证券代码：300639 证券简称：凯普生物 公告编号：2025-059 广东凯普生物科技股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或者重大遗漏。 广东凯普生物科技股份有限公司（以下简称"公司"）于 2025 年 10 月 13 日召开第六届董事会第二次会议，审议通过了《关于为全资子公司提供担保并置 换银团贷款项下部分抵押物的议案》，同意公司为全资子公司广东凯普医学科技 产业有限公司（以下简称"凯普医学产业"）向银团申请贷款提供抵押担保，并 置换银团贷款项下的部分抵押物。现将相关情况公告如下： 一、公司银团贷款的基本情况 2022 年 5 月 11 日，公司召开第四届董事会第三十五次会议和第四届监事会 第三十次会议，审议通过了《关于公司拟投资建设凯普医学科学园的议案》，同 意公司在广东省潮州市潮安区大岭山产业园投资建设凯普医学科学园项目。项目 已于 2022 年 9 月开始动工建设。截至目前，项目已完成一期生产基地的施工并 完成竣工验收备案，正在进行内部装修。 2023 年 3 月 31 日，为加快项目推进，保障项目建设资金及时到位，公司召 开第五届董事会 ...

证券代码：300639 证券简称：凯普生物 公告编号：2025-060 广东凯普生物科技股份有限公司 一、募集资金基本情况 经中国证券监督管理委员会《关于同意广东凯普生物科技股份有限公司向特 定对象发行股票注册的批复》（证监许可[2020]1713 号）同意，公司向包括实 际控制人之一、董事、常务副总经理管秩生先生在内的 8 名特定对象发行人民币 普通股（A 股）22,945,804 股，每股发行价格为人民币 45.76 元，募集资金总额 为人民币 105,000.00 万元，扣除发行费用（不含税）人民币 2,258.04 万元后的 募集资金净额为 102,741.96 万元。立信会计师事务所（特殊普通合伙）于 2020 年 9 月 7 日对本次募集资金到位情况进行了审验，并出具了"信会师报字[2020] 第 ZI10573 号"《验资报告》。公司对募集资金进行了专户存储，并与保荐机构、 存放募集资金的商业银行签署了募集资金监管协议。 二、使用自有资金支付募投项目人员费用并以募集资金等额置换的操作流 程 关于使用募集资金置换自有资金预先支付的募投项目人员费用的公 告 本公司及董事会全体成员保证信息披露的内容真 ...

第六届董事会第二次会议决议公告 证券代码：300639 证券简称：凯普生物 公告编号：2025-058 广东凯普生物科技股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 广东凯普生物科技股份有限公司（以下简称"公司"）第六届董事会第二次会 议于 2025 年 10 月 9 日以电子邮件、电话通讯等形式发出通知。本次会议于 2025 年 10 月 13 日 10:00 在广东省潮州市经济开发试验区北片高新区 D5-3-3-4 小区公司 会议室通过现场表决和通讯表决相结合的方式召开。本次会议应出席董事 9 名，实 际出席董事 9 名。公司高级管理人员列席了本次会议。会议由董事长管乔中先生主 持。会议的召集和召开符合《中华人民共和国公司法》等法律法规及《公司章程》 的规定。 二、董事会会议审议情况 1、审议通过了《关于为全资子公司提供担保并置换银团贷款项下部分抵押物 的议案》； 鉴于公司全资子公司广东凯普医学科技产业有限公司（以下简称"凯普医学产 业"）持有的位于广东省潮州市潮安区大岭山产业园规划纵二路与外环北路交界处 东北侧 G ...

证券代码：300639 证券简称：凯普生物 公告编号：2025-057 广东凯普生物科技股份有限公司 关于公司及子公司获得发明专利授权的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述 或者重大遗漏。 发明 3 属于基因检测技术领域，公开了一种多重 PCR 引物和探针组合物及试剂盒。 α‑ 地中海贫血（简称α‑ 地贫） 是一组因α‑ 珠蛋白基因（简称α基因） 变异（突变、 缺失、重组） 导致α‑ 珠蛋白缺失或合成减少所引起的遗传性慢性溶血性贫血症，本发 明针对包括 Fusion gene、ααα anti3.7和ααα anti4.2在内的 19 种α基因变异，构建得到了一种 可通过两管反应体系，利用相同反应条件同时检测所述 19 种α基因变异的多重 PCR 引物 和探针组合物。基于所述组合物，本发明通过将所述组合物中的探针序列固定在固相载 体上制成基因芯片，结合多重 PCR 和导流杂交实现了所述 19 种α基因变异及所测样本基 因型的可视化检测，检测特异性好，准确性和灵敏度高且操作简单，耗时短，结果易读， 有利于α基因变异的携带筛查，可为α‑ 地中海贫血的临床诊断或遗 ...

Core Viewpoint - The company, Capbio, announced that its wholly-owned subsidiary, Guangzhou Capbio Medical Technology Co., Ltd., has obtained the Medical Device Registration Certificate for in vitro diagnostic reagents from the National Medical Products Administration of China for its six-pathogen respiratory nucleic acid detection kit (PCR-fluorescent probe method) [2] Group 1 - Capbio's subsidiary has received regulatory approval for a new diagnostic product [2] - The approved product is designed for the detection of multiple respiratory pathogens [2]

Group 1 - The core point of the article is that Capstone Bio (300639.SZ) has received a medical device registration certificate from the National Medical Products Administration for its in vitro diagnostic reagent kit [1] - The product is named "Six Pathogen Nucleic Acid Detection Kit for Respiratory Tract" and is designed for qualitative detection of nucleic acids from various respiratory pathogens [1] - The kit can detect nucleic acids of respiratory syncytial virus, influenza A virus, influenza B virus, adenovirus, parainfluenza virus, and Mycoplasma pneumoniae from nasopharyngeal swab samples [1]

Core Viewpoint - The company announced that its wholly-owned subsidiary, Guangzhou Capbio Medical Technology Co., Ltd., has received the Medical Device Registration Certificate from the National Medical Products Administration for six respiratory pathogen nucleic acid detection kits [1] Group 1 - The detection kits utilize PCR-fluorescent probe method for in vitro qualitative detection of nucleic acids in throat swab samples [1] - The kits are designed to detect respiratory syncytial virus, influenza A virus, influenza B virus, adenovirus, parainfluenza virus, and Mycoplasma pneumoniae [1]

Group 1 - The core point of the article is that Capbio has received a medical device registration certificate for its "Six Pathogen Nucleic Acid Detection Kit" from the National Medical Products Administration of China [1] - Capbio's revenue composition for the first half of 2025 is as follows: molecular diagnostic products account for 67.65%, medical testing services account for 29.07%, and medical service income accounts for 3.27% [1] - As of the report date, Capbio's market capitalization is 3.7 billion yuan [1] Group 2 - The article also mentions a competitive situation in the beverage industry, where Nongfu Spring's new green bottle has led to a significant decline in market share for Yibao, dropping nearly 5 percentage points [1]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或者重大遗漏。 广东凯普生物科技股份有限公司（以下简称"公司"）的全资子公司广州凯 普医药科技有限公司近日取得国家药品监督管理局颁发的《中华人民共和国医疗 器械注册证（体外诊断试剂）》。具体情况如下： | 产品名称 | 注册 | 注册证编号 | 注册证有 效期 | | 预期用途 | | --- | --- | --- | --- | --- | --- | | | 分类 | | | | | | 六项呼吸道病 | 类 III | | 2025 | 年 9 | 本试剂盒用于体外定性检测人口咽 | | 原体核酸检测 | | 国 械 注 准 | 月 29 | 日至 | 拭子样本中呼吸道合胞病毒、甲型 | | 试剂盒（PCR- | | 20253401988 | 2030 | 年 9 | 流感病毒、乙型流感病毒、腺病毒、 | | 荧光探针法） | | | 月 28 | 日 | 副流感病毒和肺炎支原体的核酸。 | 一、医疗器械注册证的具体情况 证券代码：300639 证券简称：凯普生物 公告编号：2025-056 广东凯普生物科技股份有限 ...

Core Viewpoint - The company, once thriving due to its nucleic acid testing business, is now facing significant challenges in the post-pandemic era, including declining revenues, increased losses, and strategic, financial, and innovation hurdles [1][6]. Revenue and Profitability - In the first half of 2025, the company's revenue decreased by 23% year-on-year, with a net loss expanding to 89.59 million yuan, marking two consecutive years of losses [1]. - The company reported a total net loss of 650 million yuan for the entire year of 2024, indicating a severe downturn in financial performance [2]. Cost Management Efforts - To mitigate financial pressure, the company has implemented workforce reductions and salary cuts, decreasing its employee count from 3,339 in 2022 to 2,205 in 2024, and reducing average employee compensation from 266,500 yuan to 150,000 yuan [2]. - Despite these cost-cutting measures, losses in the first half of 2025 still increased by 16% year-on-year, suggesting that mere cost reduction is insufficient to reverse the downward trend [2]. Market Challenges - The company's HPV testing business, which previously accounted for over 80% of its revenue, is now facing pricing pressures due to collective procurement policies, leading to a 28% year-on-year decline in revenue from its molecular diagnostics segment in the first half of 2025 [3]. - The increase in VAT from 3% to 13% has further impacted the profitability of core products, highlighting the company's vulnerability in a competitive pricing environment [3]. Investment and Cash Flow Issues - The company is investing heavily in new growth areas, including the establishment of 31 medical laboratories and a 1.512 billion yuan investment in the KaiPu Medical Science Park, which is only 16.35% complete, with a funding gap of nearly 400 million yuan [4]. - The company is also planning to develop the Guangdong Kanghe Hospital, but the healthcare sector typically requires 5-10 years to achieve a return on investment, exacerbating cash flow pressures amid declining core business revenues [4]. Accounts Receivable and Financial Stability - As of June 2025, the company's accounts receivable stood at 1.93 billion yuan, with 990 million yuan already provisioned for bad debts, indicating a significant amount of capital tied up in long-recovery receivables from pandemic-related testing services [5]. - The company has applied for a 900 million yuan syndicated loan to support the construction of the science park, but the dual investment in the science park and hospital has strained its financial resources, raising concerns about potential refinancing pressures if receivables are not collected as expected [5]. Conclusion - The company's challenges reflect broader issues within the in vitro diagnostics industry, including policy, market, and innovation pressures. The ability to manage accounts receivable, control investment pace, and overcome technological barriers will be crucial for the company's sustainable transformation [6].